Breakthrough RNAi Therapy VSA001: A Milestone in the Treatment of Familial Chylomicronemia Syndrome

In recent years, with the rapid development of gene silencing technology, RNA interference (RNAi) therapy has gradually become a star in the biopharmaceutical field.March 17Visirna announced that its self-developed RNAi drug VSA001 Injection (Pulersiran Sodium) achieved a major breakthrough in the Phase III clinical trial in China targeting patients with Familial Chylomicronemia Syndrome (FCS), successfully reaching the primary efficacy endpoint and all key secondary endpoints. This news not only brings new hope to FCS patients but also injects strong innovative momentum into the cardiovascular field.

VSA001: A Revolutionary Breakthrough in RNAi Therapy

VSA001 is a globally pioneering RNAi therapeutic drug designed to effectively reduce serum triglycerides and triglyceride-rich lipoprotein levels by decreasing the mRNA levels of apolipoprotein C3 (APOC3) and thereby lowering the expression of the APOC3 protein. Its unique mechanism of action operates through both lipoprotein lipase-dependent and -independent pathways, offering a novel treatment option for hypertriglyceridemia and related conditions.

In this Phase III clinical trial, VSA001 demonstrated excellent efficacy and safety:

• Primary Endpoint
  : At the 10th month, the fasting serum triglyceride levels in the 25 mg and 50 mg dose groups decreased by 86% and 89%, respectively, compared to baseline.
• Long-term efficacy
  : At the 12th month, the reduction rates for the 25 mg and 50 mg dose groups were 72% and 79%, respectively, demonstrating sustained and stable therapeutic effects.
• APOC3 Levels Significantly Decreased
  : At Month 10, the median reductions from baseline in serum APOC3 were 93% and 92% for the 25 mg and 50 mg dose groups, respectively.
• Good safety profile
  : VSA001 demonstrated good tolerability in FCS patients, with a treatment-related adverse event (TEAE) rate comparable to the placebo group, and a lower incidence of severe adverse events than the placebo group.

These data indicate that VSA001 not only significantly reduces triglyceride levels in FCS patients but also demonstrates excellent long-term efficacy and safety, setting a new benchmark for FCS treatment.

Good News for FCS Patients: From No Available Drugs to Precision Treatment

Familial Chylomicronemia Syndrome (FCS) is a rare hereditary disease. Due to the functional defect of lipoprotein lipase, patients experience extremely high levels of serum triglycerides, which can easily lead to severe complications such as acute pancreatitis. For a long time, FCS patients have lacked effective drug treatments and could only manage their condition through strict dietary control, significantly impacting their quality of life.

The emergence of VSA001 has completely transformed this situation. As the first RNAi therapy targeting FCS, VSA001 fundamentally addresses the core pathological issues of FCS patients by precisely targeting APOC3. Notably, in the 25 mg dose group, up to 90% of patients achieved fasting serum triglyceride levels below 500 mg/dL by the 10th month, marking a new era in FCS treatment.

Global R&D Progress: VSA001 Leads the Industry Trend

Globally, the development progress of VSA001 is far ahead. According to the Insight database, VSA001 is currently the only APOC3 siRNA drug that has entered Phase III clinical trials. Additionally, its partner, Arrowhead Pharmaceuticals, submitted a New Drug Application (NDA) to the U.S. FDA for VSA001 in treating FCS in November 2024, with the PDUFA action date set for November 18, 2025. Meanwhile, the marketing application for VSA001 in China was submitted in January 2025, and it is expected to benefit more Chinese patients in the near future.

In addition to FCS indications, VSA001 is also conducting a series of clinical studies targeting other hypertriglyceridemia-related diseases, including:

• PALISADE Phase III Study
  : Further validation for FCS patients.
• SHASTA Study
  : For patients with severe hypertriglyceridemia (SHTG).
• MUIR and CAPITAN Studies
  : For patients with mixed hyperlipidemia.

These studies will further expand the application scope of VSA001, bringing good news to more patients with cardiovascular diseases.

Competitive Landscape: Chinese Enterprises Begin to Emerge

Despite VSA001's leading position in the APOC3 siRNA field, companies in China are also accelerating their development. Currently, four similar products have entered clinical stages, with over 70% being domestically developed projects. Although most are still in the early stages, they demonstrate China's rapid rise in the RNAi field.

However, VSA001, with its excellent clinical data and leading development progress, has undoubtedly become the benchmark product in this field. Its success not only represents a major breakthrough in RNAi technology but also sets an example for the international development of China's biopharmaceutical industry.

Conclusion: The Future of RNAi Therapy is Promising

The success of VSA001 is not only a leap forward in FCS treatment but also an important milestone in the application of RNAi therapy in the cardiovascular field. As VSA001 gradually receives approval worldwide, there is good reason to believe that this precise, targeted, efficient, and safe treatment will bring hope of a cure to more patients.